Description
A CYP17A1 inhibitor (IC50s = 17 and 18 nM for inhibition of C17,20-lyase and 17α-hydroxylase activities, respectively); prodrug form of abiraterone; reduces plasma testosterone levels, increases plasma luteinizing hormone levels, and reduces ventral prostate, seminal vesicle, testis, and kidney weight in mice at 0.1 and 0.5 mmol/kg per day; reduces SARS-CoV-2 viral load in the culture supernatant of infected Vero E6 cells (EC90 = 8.4 μM) and is active in a plaque reduction assay (EC50 = 1.94 μM)
Formal name: (3β)-17-(3-pyridinyl)-androsta-5,16-dien-3-ol, acetate ester
Synonyms: CB-7630
Molecular weight: 391.6
CAS: 154229-18-2
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Antivirals||Product Type|Biochemicals|Lipids|Sterol Lipids||Product Type|Biochemicals|Small Molecule Inhibitors|Cytochrome P450||Product Type|Biochemicals|Small Molecule Inhibitors|Sterol Biosynthesis||Research Area|Cancer||Research Area|Endocrinology & Metabolism|Hormones & Receptors|Androgens||Research Area|Endocrinology & Metabolism|Reproductive Biology||Research Area|Immunology & Inflammation|Pulmonary Diseases||Research Area|Infectious Disease|Viral Diseases|Coronaviruses